Sunil Gollapudi, MD
Nephrology · Indianapolis, INNPI 1275530693
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,707 of the $6,050 with a category attached, or 61.3%. 25 manufacturers reported payments, led by Roche Diagnostics Corporation at 37.0% of the total. Reporting peaked in 2024 at $3,550 and has fallen 70.6% since, to $1,042 in 2025.
Across 172 payments — averaging $35.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$2K
- Amgen$568
- AstraZeneca$519
- Novartis$473
- Mallinckrodt Hospital Products Inc.$352
- Otsuka America Pharmaceutical, Inc.$226
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,24037%
- Food & beverage$3,70761%
- Education$1032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 1 | $2,240 |
| Amgen(2 entities) | 45 | $568 |
| AstraZeneca(2 entities) | 15 | $519 |
| Novartis | 22 | $473 |
| Mallinckrodt Hospital Products Inc. | 8 | $352 |
| Otsuka America Pharmaceutical, Inc. | 7 | $226 |
| Bayer | 10 | $218 |
| Novo Nordisk | 9 | $197 |
| Vifor Pharma, Inc. | 6 | $167 |
| Aurinia Pharma U.S., Inc. | 8 | $163 |
| Calliditas Therapeutics US Inc. | 7 | $162 |
| Boehringer Ingelheim | 7 | $139 |
| Ardelyx, Inc. | 6 | $118 |
| Johnson & Johnson | 2 | $115 |
| Travere Therapeutics, Inc. | 4 | $86 |
| Fresenius USA Marketing, Inc. | 4 | $71 |
| Nxstage Medical, Inc. | 2 | $35 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Akebia Therapeutics Inc | 1 | $23 |
| GSK | 1 | $23 |
| Merck | 1 | $20 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,050 in reported general payments places this provider in the 85th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 197 | $184,137 |
| JardianceEmpagliflozin | 91 | $118,789 |
| KerendiaFinerenone | 71 | $70,949 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $23,726 |
| Paricalcitol | 123 | $11,812 |
| Sevelamer Carbonate | 28 | $6,947 |
| Torsemide | 140 | $3,816 |
| Valsartan | 183 | $3,202 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,823 |
| Midodrine Hcl | 26 | $1,818 |
| Nifedipine ErNifedipine | 78 | $1,733 |
| Losartan Potassium | 159 | $1,525 |
| Eplerenone | 14 | $1,392 |
| Chlorthalidone | 69 | $1,092 |
| Spironolactone | 146 | $1,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $519 | $207,863225 claims |
| Boehringer IngelheimJardiance | $139 | $118,78991 claims |
| BayerKerendia | $218 | $70,94971 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 238 nephrology providers in Indiana.
Other nephrology in Indianapolis
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Muhammad MujtabaIndianapolis$71K
- Simit DoshiIndianapolis$63K
- Arjun SinhaIndianapolis$50K
- Brent MillerIndianapolis$46K
- James ElliottIndianapolis$37K
- Nupur GuptaIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.